Novel Technology can Diagnose Sickle Cell Disease in Record Time

Novel Acousto Thermal Shift Assay (ATSA) can diagnose diseases of the blood such as sickle cell disease with sensitivity and accuracy and in only one minute, reports a new study.

New study has developed a new way to diagnose blood diseases such as sickle cell disease with sensitivity and accuracy and in only one minute. The technology is smaller than a quarter and needs only a small droplet of blood to measure protein interactions, dysfunction, or mutations, reports a new study. The findings of the study are published in the journal Small.

"Sickle cell disease is the main cause of death in five percent of kids under five years old for lack of early diagnosis, in Africa," stated Angelo D'Alessandro, the coauthor of the study. "This common, life-threatening genetic condition is most prevalent in poor regions of the globe where newborn screening and diagnosis are rare."

Sickle Cell Anemia–Causes-Symptoms-Diagnosis-Treatment–Prognosis
Sickle cell anemia (SCA) is a genetic blood disorder caused by abnormal inherited hemoglobin. Sickle cell anemia is the most common form of sickle cell disease.

‘Sickle cell disease affects hemoglobin levels, the molecule in red blood cells that delivers oxygen to cells throughout the body. ’

Almost all life activities involve proteins. Hence, the investigators thought if they could measure the protein thermal stability change, they could detect these diseases that impact the protein stability.

Proteins have a distinct solubility at a particular temperature. When the protein is mutated or when one bonds to another, the solubility alters. By assessing solubility at various temperatures, experts can find whether the protein has been mutating.

The investigators used Acousto Thermal Shift Assay (ATSA) to assess protein stability under altering conditions. ATSA uses ultrasound, or high-amplitude sound waves, to heat a protein sample. The tool then assessed data continuously, recording how much of the protein has melted at every fraction of change in degrees Celsius.

Positive Gene Editing for Sickle Cell Disease and Beta Thalassemia
New approach to gene editing for major blood disorders such as sickle cell disease and beta-thalassemia has been optimized. CRISPR-Cas9 gene editing can edit out diseased genes in blood disorders.

"Our design is seven to 34 times more sensitive," stated Ding. "The ATSA can identify the sickle cell protein from normal protein, while the traditional TSA method cannot."

Another advantage of the ATSA is cost reduction in terms of human labor and equipment.

Sickle Cell Anemia Gets a New Ray of Hope
Sickle cell anemia is a devastating blood disorder that can cause early death. With advances in gene therapeutics, new study focus on correcting the disease at the genetic level.

Source-Medindia

How Does Acute Pain Crisis in Sickle Cell Disease Arise?
Steps leading to a sickle-cell disease complication that causes acute pain have been explained by MIT researchers.